Year All2024202320222021202020192018201720162015 Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting November 8, 2017 Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma October 26, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 5, 2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma September 26, 2017 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit September 6, 2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting June 5, 2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy May 22, 2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting April 4, 2017 Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs January 3, 2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting December 5, 2016
Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting November 8, 2017
Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma October 26, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 5, 2017
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma September 26, 2017
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting June 5, 2017
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy May 22, 2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting April 4, 2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting December 5, 2016
